Abstract: Globally， there are approximately 258 million individuals living with chronic hepatitis B （CHB）， resulting in about 1.1 million deaths annually due to hepatitis B-related cirrhosis and hepatocellular carcinoma. Data from the United States suggest that the actual burden of infection may be as high as 1.8 million， with around half of those infected remaining undiagnosed. In November 2025， the American Association for the Study of Liver Diseases （AASLD） and the Infectious Diseases Society of America （IDSA） jointly released an updated practice guideline for the management of CHB， which was developed based on previous guideline recommendations and the latest evidence-based research. This article provides a translated summary of the key recommendations from this guideline.